Abstract
Portal hypertension is a severe, almost unavoidable complication of chronic liver diseases and is responsible for the main clinical consequences of cirrhosis. Measurement of the hepatic venous pressure gradient (HVPG) is currently the best available method to evaluate the presence and severity of portal hypertension. Clinically significant portal hypertension is defined as an increase in HVPG to ≥10 mmHg; above this threshold, the complications of portal hypertension might begin to appear. Measurement of HVPG is increasingly used in clinical hepatology, and numerous studies have demonstrated that the parameter is a robust surrogate marker for hard clinical end points. The main clinical applications for HVPG include diagnosis, risk stratification, identification of patients with hepatocellular carcinoma who are candidates for liver resection, monitoring of the efficacy of medical treatment, and assessment of progression of portal hypertension. Patients who experience a reduction in HVPG of ≥20% or to <12 mmHg in response to drug therapy are defined as 'responders'. Responders have a markedly decreased risk of bleeding (or rebleeding), ascites, and spontaneous bacterial peritonitis, which results in improved survival.
Key Points
-
Measurement of the hepatic venous pressure gradient (HVPG) is the gold standard technique for evaluation of portal hypertension in liver disease
-
In patients with cirrhosis, HVPG measurement provides independent prognostic information on survival and the risk of decompensation
-
The HVPG response to pharmacological therapy enables the identification of patients with portal hypertension who are most likely to benefit from treatment
-
Measurement of HVPG helps to assess the risk of liver failure and death after liver resection in patients with compensated chronic liver disease or hepatocarcinoma
-
No noninvasive alternatives to HVPG measurement are currently available
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Garcia-Tsao, G. et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 5, 419–424 (1985).
Groszmann, R. J. et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 99, 1401–1407 (1990).
Groszmann, R. J. & Wongcharatrawee, S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 39, 280–282 (2004).
Bosch, J., Garcia-Pagan, J. C., Berzigotti, A. & Abraldes, J. G. Measurement of portal pressure and its role in the management of chronic liver disease. Semin. Liver Dis. 26, 348–362 (2006).
Perello, A. et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 30, 1393–1397 (1999).
Bosch, J., Abraldes, J. G., Berzigotti, A. & Garcia-Pagan, J. C. Portal hypertension and gastrointestinal bleeding. Semin. Liver Dis. 28, 3–25 (2008).
Keiding, S. & Vilstrup, H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. Scand. J. Gastroenterol. 37, 960–964 (2002).
Steinlauf, A. F. et al. Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements. Hepatology 29, 1070–1073 (1999).
de Franchis, R., Dell'Era, A. & Primignani, M. Diagnosis and monitoring of portal hypertension. Dig. Liver Dis. 40, 312–317 (2008).
Vizzutti, F., Arena, U., Rega, L. & Pinzani, M. Non-invasive diagnosis of portal hypertension in cirrhotic patients. Gastroenterol. Clin. Biol. 32, 80–87 (2008).
Groszmann, R. J. et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Engl. J. Med. 353, 2254–2261 (2005).
Casado, M. et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114, 1296–1303 (1998).
Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481–488 (2007).
Valla, D. C. & Condat, B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J. Hepatol. 32, 865–871 (2000).
Gluud, C., Brok, J., Gong, Y. & Koretz, R. L. Hepatology may have problems with putative surrogate outcome measures. J. Hepatol. 46, 734–742 (2007).
Burroughs, A. K. et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 50, 425–427 (2002).
Kumar, M. et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int. 28, 690–698 (2008).
Rincon, D. et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am. J. Gastroenterol. 101, 2269–2274 (2006).
Roberts, S. et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin. Gastroenterol. Hepatol. 5, 932–937 (2007).
Poynard, T., Degott, C., Munoz, C. & Lebrec, D. Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis. Effect of acute alcoholic hepatitis on portal hypertension. Dig. Dis. Sci. 32, 337–343 (1987).
Sen, S. et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J. Hepatol. 43, 142–148 (2005).
Rincon, D. et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment. Pharmacol. Ther. 25, 841–848 (2007).
Ripoll, C. et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era. Hepatology 42, 793–801 (2005).
Blasco, A. et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43, 492–499 (2006).
Carrion, J. A. et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl. 12, 1791–1798 (2006).
Samonakis, D. N. et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl. 13, 1305–1311 (2007).
Kalambokis, G. et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl. Int. 22, 172–181 (2009).
Carrion, J. A. et al. Efficacy of antiviral therapy on hepatitis c recurrence after liver transplantation: a randomized controlled study. Gastroenterology 132, 1746–1756 (2007).
Ripoll, C. et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J. Hepatol. 50, 923–928 (2009).
Bruix, J. et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111, 1018–1022 (1996).
Llovet, J. M., Fuster, J. & Bruix, J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30, 1434–1440 (1999).
Forner, A. & Bruix, J. East meets the West-—portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 6, 14–15 (2009).
Lebrec, D., De Fleury, P., Rueff, B., Nahum, H. & Benhamou, J. P. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 79, 1139–1144 (1980).
D'Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231 (2006).
Merkel, C. et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology 102, 973–979 (1992).
Vorobioff, J. et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 111, 701–709 (1996).
Gluud, C., Henriksen, J. H. & Nielsen, G. Prognostic indicators in alcoholic cirrhotic men. Hepatology 8, 222–227 (1988).
de Franchis, R. Evolving consensus in portal hypertension: report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 43, 167–176 (2005).
Garcia-Tsao, G., Bosch, J. & Groszmann, R. J. Portal hypertension and variceal bleeding-—unresolved issues: summary of an American Association for the Study of Liver Diseases and European Association for the Study of the Liver single-topic conference. Hepatology 47, 1764–1772 (2008).
Bosch, J., Abraldes, J. G. & Groszmann, R. J. Current management of portal hypertension. J. Hepatol. 38, S54–S68 (2003).
Garcia-Pagan, J. C. et al. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 11, 230–238 (1990).
Albillos, A. et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 115, 116–123 (1998).
Banares, R. et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 36, 1367–1373 (2002).
Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651–1658 (2009).
Feu, F. et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346, 1056–1059 (1995).
Turnes, J. et al. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am. J. Gastroenterol. 101, 506–512 (2006).
Tage-Jensen, U. et al. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J. Hepatol. 6, 350–358 (1988).
Merkel, C. et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 32, 930–934 (2000).
Stanley, A. J., Robinson, I., Forrest, E. H., Jones, A. L. & Hayes, P. C. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. QJM 91, 19–25 (1998).
Urbain, D. et al. Prognostic significance of hepatic venous pressure gradient in medically treated alcoholic cirrhosis: comparison to aminopyrine breath test. Am. J. Gastroenterol. 88, 856–859 (1993).
Moitinho, E. et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 117, 626–631 (1999).
Monescillo, A. et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 40, 793–801 (2004).
Abraldes, J. G. et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J. Hepatol. 48, 229–236 (2008).
D'Amico, G., Garcia-Pagan, J. C., Luca, A. & Bosch, J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 131, 1611–1624 (2006).
Abraldes, J. G. et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37, 902–908 (2003).
Villanueva, C. et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J. Hepatol. 40, 757–765 (2004).
Garcia-Pagan, J. C. et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomized controlled trial. Gut 58, 1144–1150 (2009).
LaMura, V. et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J. Hepatol. 51, 279–287 (2009).
Villanueva, C. et al. Acute hemodynamic response to β-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology 137, 119–128 (2009).
Bosch, J. & Garcia-Pagan, J. Prevention of variceal rebleeding. Lancet 361, 952–954 (2003).
Bureau, C. et al. “A la carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 36, 1361–1366 (2002).
Gonzalez, A. et al. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology 44, 806–812 (2006).
Garcia-Pagan, J. C. et al. An early decision for PTFE-TIPS improves survival in high risk cirhotic patients admitted with an acute variceal bleeding: a multicentric RCT [abstract 992]. J. Hepatol. 48, S371 (2008).
Acknowledgements
This work is supported in part by grants from Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (FIS 06/0623, FIS 08/0193 and SAF 07/61298). CIBERehd is funded by Instituto de Salud Carlos III.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bosch, J., Abraldes, J., Berzigotti, A. et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 6, 573–582 (2009). https://doi.org/10.1038/nrgastro.2009.149
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.149
This article is cited by
-
Tissue inhibitor of matrix metalloprotinase-1 and collagen type IV in HCV-associated cirrhosis and grading of esophageal varices
Egyptian Liver Journal (2024)
-
Predictors and Outcomes of Post-transjugular Intrahepatic Portosystemic Shunt Liver Failure in Patients with Cirrhosis
Digestive Diseases and Sciences (2024)
-
Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates
Cancer Imaging (2023)
-
Performance of spleen stiffness measurement by 2D-shear wave elastography in evaluating the presence of high-risk varices: comparative analysis of idiopathic portal hypertension versus hepatitis B virus
BMC Medical Imaging (2023)
-
Innovative angiography: a new approach to discover more hepatic vein collaterals in patients with cirrhotic portal hypertension
BMC Gastroenterology (2023)